All data are based on the daily closing price as of October 30, 2026
s

Samsung Biologics

207940.KO
1113.98 USD
92.81
+9.09%

Overview

Last close
1113.98 usd
Market cap
51.86B usd
52 week high
1154.38 usd
52 week low
655.09 usd
Target price
749.93 usd

Valuation

P/E
34.3866
Forward P/E
34.6021
Price/Sales
13.5173
Price/Book Value
7.605
Enterprise Value
46.96B usd
EV/Revenue
12.2276
EV/EBITDA
20.918

Key financials

Revenue TTM
3.84B usd
Gross Profit TTM
2.08B usd
EBITDA TTM
2.12B usd
Earnings per Share
29.79 usd
Dividend
N/A usd
Total assets
8.18B usd
Net debt
437.33M usd

About

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
  • Symbol
    207940.KO
  • Exchange
    KO
  • Isin
    KR7207940008
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. John Chongbo Rim
  • Headquarter
    Incheon
  • Web site
    https://samsungbiologics.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top